Amgen May 1, 2026 Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data - Fierce Biotech
Amgen Apr 29, 2026 Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials - BioSpace
Amgen Apr 28, 2026 FDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on board - Fierce Biotech
Amgen Apr 28, 2026 FDA turns up heat on Amgen, proposing to rescind approval of Tavneos - Fierce Pharma
Amgen Apr 24, 2026 Amgen’s Chief Technology Officer Dr David Reese to retire - European Pharmaceutical Review
Amgen Apr 20, 2026 Zurcher Kantonalbank Zurich Cantonalbank Buys 55,333 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Apr 16, 2026 Federal Circuit Distinguishes Amgen in Reversal of Invalidation of Teva Headache Treatment Patents - IPWatchdog.com
BioPharma Dive Apr 6, 2026 Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Endpoints News Apr 6, 2026 Amgen seeks to buoy Tepezza with injectable data in face of incoming competition